USMF logo

Institutional Repository in Medical Sciences
of Nicolae Testemitanu State University of Medicine and Pharmacy
of the Republic of Moldova
(IRMS – Nicolae Testemitanu SUMPh)

Biblioteca Stiintifica Medicala
DSpace

University homepage  |  Library homepage

 
Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12710/34605
Title: 2025 KDIGO GUIDELINES: NEW STANDARDS IN THE MANAGEMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE
Authors: Moisei, Tatiana
Gutu, Biatricia
Sasu, Dorian
Rotaru, Larisa
Keywords: autosomal dominant polycystic kidney disease;ADPKD;KDIGO 2025;tolvaptan;quality of life
Issue Date: 2026
Publisher: Centrul Editorial-Poligrafic Medicina
Citation: Moisei, Tatiana; Gutu, Biatricia; Sasu, Dorian; Rotaru, Larisa. 2025 KDIGO GUIDELINES: NEW STANDARDS IN THE MANAGEMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE. In: MedEspera 2026, p. 790. ISBN 978-9975-82-486-6.
Abstract: Introduction. Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disorder, characterized by progressive cyst formation, increasing kidney volume, and a gradual decline in renal function. It is a leading cause of chronic kidney disease, accounting for 5 -10% of all end-stage kidney disease (ESKD) cases. Its heterogeneous clinical course necessitates early standardized risk assessment and individualized management strategies. Aim of study. To analyze current data regarding early diagnosis, risk stratification, and management of ADPKD, with a specific focus on the updates and clinical recommendations introduced by the KDIGO 2025 guideline. Methods and materials. A comprehensive review of the KDIGO 2025 guideline for ADPKD was conducted, evaluating recommendations developed by international experts using the GRADE methodology. Results. The KDIGO 2025 guideline recommends stratifying disease progression risk using the Mayo imaging classification and the PROPKD score. The Mayo classification, based on height-adjusted total kidney volume (htTKV), categorizes patients into classes 1A-1E; classes 1C-1E indicate rapid progression and identify candidates for disease-modifying therapy. The PROPKD score integrates genetic and clinical parameters (mutation type, hypertension onset, gross hematuria, gender) to stratify patients into low-, intermediate-, and high-risk categories for ESKD. Tolvaptan is recommended for adults with rapidly progressive ADPKD and an eGFR > 25 ml/min/1.73 m2. Strict liver function monitoring is mandatory due to hepatotoxicity risks. Caution is advised in patients with gout due to potential hyperuricemia. Additionally, the guideline emphasizes individualized screening for intracranial aneurysms and outlines a complex management approach for women, including preconception and genetic counseling. Conclusions. The KDIGO 2025 guideline marks a significant advance in ADPKD management by promoting early progression assessment and detailed risk identification. It advocates for an integrated approach that addresses renal and extrarenal manifestations as well as the psychosocial dimensions of the disease.
metadata.dc.relation.ispartof: MedEspera 2026. The 11th International Medical Congress for Students and Young Doctors, 6-8 May 2026
URI: https://medespera.md/documents/abstract-book-4.pdf
https://repository.usmf.md/handle/20.500.12710/34605
ISBN: 978-9975-82-486-6
Appears in Collections:MedEspera 2026

Files in This Item:
File Description SizeFormat 
M_790.pdf466 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2013  Duraspace - Feedback